Navigation path

Pharmaceuticals - Community Register

  

Community list of not active orphan medicinal products


WITHDRAWN  

Product information

(1S, 2S, 3R, 4R)-3-(5-Fluoro-2-(3-methyl-4-(4-methylpiperazin-1-yl)-phenylamino)-pyrimidin-4-ylamino)-bicyclo[2.2.1]hept-5-ene-2-carboxamide benzoate

EU orphan designation number: EU/3/10/729
Active ingredient: (1S, 2S, 3R, 4R)-3-(5-Fluoro-2-(3-methyl-4-(4-methylpiperazin-1-yl)-phenylamino)-pyrimidin-4-ylamino)-bicyclo[2.2.1]hept-5-ene-2-carboxamide benzoate
Indication: Treatment of acute myeloid leukaemia
Sponsor: Merck KGaA
Frankfurter Straße 250, D-64293 Darmstadt, Deutschland

   Public summary of scientific opinion    

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
25/03/2010 Centralised Orphan - Designation EMEA/OD/132/09 (2010)2055 of 23/03/2010